AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36343030 — intervention group
Group type: COMPARATOR
Intervention: Placebo ILIB combined with orofacial myofunctional therapy (MFT) exercise protocol; placebo treatment is performed twice a week for 8 weeks.
Number of subjects: 46
Study 34018029 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib-obinutuzumab
Number of subjects: 228
Study 34018029 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil-obinutuzumab
Number of subjects: 228
Study 34018029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 228
Study 35662408 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib (80 mg/day)
Number of subjects: 358
Study 35662408 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg/day)
Number of subjects: 358
Study 33002700 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane distillation (MD) powered by waste heat
Number of subjects: 20
Study 33002700 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane distillation (MD) powered by natural gas
Number of subjects: 20
Study 36193750 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-Directed Medical Therapy (GDMT) goals achieved
Number of subjects: 777
Study 36193750 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 777
Study 36193750 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 777
Study 34731918 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration with anesthetic solution and adjuvants (fentanyl, epinephrine, ketorolac)
Number of subjects: 40
Study 34731918 — intervention group
Group type: COMPARATOR
Intervention: Placebo infiltration
Number of subjects: 40
Study 35881302 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% SDF
Number of subjects: 40
Study 35881302 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% SDF
Number of subjects: 40
Study 35881302 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% SDF
Number of subjects: 40
Study 35881302 — intervention group
Group type: COMPARATOR
Intervention: Control (without SDF treatment)
Number of subjects: 40
Study 34656740 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant abemaciclib combined with endocrine therapy (ET) for 2 years
Number of subjects: 5637
Study 35477480 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers with standard care
Number of subjects: 0
Study 35477480 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard care
Number of subjects: 0
Study 32740755 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic intelligence score (gIQ) increase of one standard deviation (SD)
Number of subjects: 461389
Study 32740755 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic intelligence score (gIQ)
Number of subjects: 461389
Study 32740755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for measured intelligence and educational attainment
Number of subjects: 461389
Study 32740755 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analyses
Number of subjects: 461389
Study 36235549 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE)
Number of subjects: 10
Study 36235549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32178925 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (20 mg D0 and D4)
Number of subjects: 100
Study 32178925 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (3 mg/kg total)
Number of subjects: 100
Study 32673243 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based vision screening solution
Number of subjects: 100
Study 35041775 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-day lead-in dose at 90 mg once daily)
Number of subjects: 0
Study 34226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigated surgery
Number of subjects: 127
Study 34226082 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 127
Study 34226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 34969498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1494
Study 34969498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1494
Study 33179263 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 0
Study 33179263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36266558 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab (240 mg loading dose)
Number of subjects: 459
Study 36266558 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg galcanezumab
Number of subjects: 459
Study 36266558 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg galcanezumab
Number of subjects: 459
Study 36266558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 33881513 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical testing
Number of subjects: 9572
Study 33881513 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 9572
Study 32497520 — intervention group
Group type: EXPERIMENTAL
Intervention: 39·0°C ear temperature limit
Number of subjects: 269
Study 32497520 — intervention group
Group type: COMPARATOR
Intervention: 38·5°C ear temperature limit
Number of subjects: 269
Study 35048733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy plus optional delayed ACL reconstruction
Number of subjects: 167
Study 35048733 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACL reconstruction
Number of subjects: 167
Study 35048733 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 167
Study 34036929 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral aid for smoking cessation guidance provided by practice nurses (PNs) in accordance with the referral aid.
Number of subjects: 0
Study 34036929 — intervention group
Group type: COMPARATOR
Intervention: Standard care without the referral aid (control condition).
Number of subjects: 0
Study 34036929 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral aid for smoking cessation guidance provided by practice nurses (PNs).
Number of subjects: 0
Study 34076285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid suture pattern
Number of subjects: 16
Study 34076285 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure‐8 suture pattern
Number of subjects: 16
Study 34076285 — intervention group
Group type: COMPARATOR
Intervention: Simple interrupted suture pattern
Number of subjects: 16
Study 32944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy (800-1600 mg/d)
Number of subjects: 206
Study 32944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy (ESL/ESL)
Number of subjects: 206
Study 32944934 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (CBZ-CR) followed by ESL monotherapy (CBZ-CR/ESL)
Number of subjects: 206
Study 32944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy
Number of subjects: 206
Study 35973827 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoHeal® (500 mg/d)
Number of subjects: 40
Study 35973827 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoHeal® (1,000 mg/d)
Number of subjects: 40
Study 35973827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34328794 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 20
Study 34328794 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthodontic intrusion without PBM)
Number of subjects: 20
Study 36288558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride gel
Number of subjects: 220
Study 36288558 — intervention group
Group type: COMPARATOR
Intervention: Sham gel
Number of subjects: 220
Study 34156468 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute nap opportunity
Number of subjects: 280
Study 34156468 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute nap opportunity
Number of subjects: 280
Study 34156468 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who napped (30 or 60 minutes)
Number of subjects: 280
Study 34156468 — intervention group
Group type: COMPARATOR
Intervention: No nap opportunity (control group)
Number of subjects: 280
Study 32423509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol white wine (8.0% alcohol content)
Number of subjects: 90
Study 32423509 — intervention group
Group type: COMPARATOR
Intervention: Standard white wine (12.5% alcohol content)
Number of subjects: 90
Study 32423509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alcohol white wine (8.0% alcohol content) - blinded condition
Number of subjects: 90
Study 36109033 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT)
Number of subjects: 160
Study 36109033 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular exercise (NEMEX)
Number of subjects: 160
Study 36109033 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise booster sessions (EBS)
Number of subjects: 160
Study 33525601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination (Bifidobacterium longum BB536, red yeast rice extract (10 mg/dose monacolin K))
Number of subjects: 33
Study 33525601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 32162958 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 53
Study 32162958 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE)
Number of subjects: 53
Study 32162958 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 53
Study 36101936 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 6051
Study 33292693 — intervention group
Group type: EXPERIMENTAL
Intervention: iVERVE intervention (electronic support messages aligned to personal goals over 4 weeks)
Number of subjects: 54
Study 33292693 — intervention group
Group type: COMPARATOR
Intervention: Control group (2-3 electronic administrative messages)
Number of subjects: 54
Study 33292693 — intervention group
Group type: EXPERIMENTAL
Intervention: iVERVE intervention
Number of subjects: 54
Study 35166384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (40 g/500 mL saline)
Number of subjects: 13
Study 35166384 — intervention group
Group type: COMPARATOR
Intervention: Glucose (40 g/500 mL saline)
Number of subjects: 13
Study 35166384 — intervention group
Group type: COMPARATOR
Intervention: Saline (500 mL)
Number of subjects: 13
Study 33347776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 184
Study 33347776 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypothermia)
Number of subjects: 184
Study 33731890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferomedial orbital decompression
Number of subjects: 42
Study 33731890 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced orbital decompression
Number of subjects: 42
Study 34479145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL)
Number of subjects: 104
Study 35549716 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) intervention with free LPG stove, continuous fuel delivery, and regular behavioral messaging for the first year.
Number of subjects: 180
Study 35549716 — intervention group
Group type: COMPARATOR
Intervention: Voucher-based LPG intervention for controls in the second year (free LPG stove, regular behavioral messaging, and vouchers for LPG tanks).
Number of subjects: 180
Study 35549716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants after free fuel distribution stopped in the second year.
Number of subjects: 180
Study 32078086 — intervention group
Group type: EXPERIMENTAL
Intervention: RY-NF (virtual mind-body group program)
Number of subjects: 51
Study 32078086 — intervention group
Group type: COMPARATOR
Intervention: HE-NF (health education attention control)
Number of subjects: 51
Study 35964137 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln/Arg/HMB supplementation (2 sachets daily: 7 g l-arginine, 7 g l-glutamine, 1.5 g HMB)
Number of subjects: 60
Study 35964137 — intervention group
Group type: EXPERIMENTAL
Intervention: Gln/Arg/HMB supplementation
Number of subjects: 60
Study 35964137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33378369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 16167
Study 34530475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizzou BioJoint Flex‐novel motion‐assistive device with prescribed physical therapy
Number of subjects: 38
Study 34530475 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy
Number of subjects: 38
Study 34831529 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance training volume-load
Number of subjects: 33
Study 34831529 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate resistance training volume-load
Number of subjects: 33
Study 34831529 — intervention group
Group type: EXPERIMENTAL
Intervention: Low resistance training volume-load
Number of subjects: 33
Study 34921960 — intervention group
Group type: EXPERIMENTAL
Intervention: A+CHP (brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 452
Study 34921960 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 452
Study 34921960 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin retreatment after A+CHP
Number of subjects: 452
Study 34921960 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin after CHOP
Number of subjects: 452
Study 33544556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy with a new airway clearance device (Simeox; PhysioAssist)
Number of subjects: 48
Study 33544556 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy alone
Number of subjects: 48
Study 32784930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 15 µg
Number of subjects: 25
Study 32784930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 30 µg
Number of subjects: 25
Study 32784930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 45 µg
Number of subjects: 25
Study 32784930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 32784930 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 25
Study 34116816 — intervention group
Group type: EXPERIMENTAL
Intervention: DynamiCare along with treatment-as-usual (TAU; N = 29)
Number of subjects: 61
Study 34116816 — intervention group
Group type: COMPARATOR
Intervention: TAU only (N = 32)
Number of subjects: 61
Study 34116816 — intervention group
Group type: EXPERIMENTAL
Intervention: DynamiCare
Number of subjects: 61
Study 33444079 — intervention group
Group type: EXPERIMENTAL
Intervention: R-miniCHOP
Number of subjects: 249
Study 33444079 — intervention group
Group type: COMPARATOR
Intervention: R2-miniCHOP
Number of subjects: 249
Study 33572715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmos caudatus supplement (250 mg of CC/capsule, twice daily for 12 weeks)
Number of subjects: 48
Study 33572715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg maltodextrin/capsule, twice daily for 12 weeks)
Number of subjects: 48
Study 32830940 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bag transfer set exchange procedure
Number of subjects: 33
Study 32830940 — intervention group
Group type: COMPARATOR
Intervention: Standard bag exchange procedure
Number of subjects: 33
Study 33452887 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorpactin 0.4% solution
Number of subjects: 50
Study 33452887 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy/hydrodistension
Number of subjects: 50
Study 32881834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 12757
Study 32881834 — intervention group
Group type: COMPARATOR
Intervention: Non-CHMs users
Number of subjects: 12757
Study 35244373 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol cardioplegia
Number of subjects: 20
Study 35244373 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 20
Study 36327028 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (standing, performing calf muscle contractions while standing, walking, and climbing stairs)
Number of subjects: 8
Study 36327028 — intervention group
Group type: COMPARATOR
Intervention: Inactivity (lying down and sitting)
Number of subjects: 8
Study 34159198 — intervention group
Group type: EXPERIMENTAL
Intervention: Si foliar applied
Number of subjects: 0
Study 34159198 — intervention group
Group type: EXPERIMENTAL
Intervention: Si topdressing
Number of subjects: 0
Study 32093665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy (50 L/min, FiO2 0.5)
Number of subjects: 20
Study 32093665 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (VM) oxygen therapy (15 L/min, FiO2 0.5)
Number of subjects: 20
Study 32093665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy (50 L/min, FiO2 0.5) in good responders
Number of subjects: 20
Study 32093665 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (VM) oxygen therapy (15 L/min, FiO2 0.5) in good responders
Number of subjects: 20
Study 71706451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus water exercise (EW) group
Number of subjects: 60
Study 71706451 — intervention group
Group type: COMPARATOR
Intervention: Exercise (E) group
Number of subjects: 60
Study 36106470 — intervention group
Group type: EXPERIMENTAL
Intervention: HP±1% quercetin for 10min
Number of subjects: 60
Study 36106470 — intervention group
Group type: EXPERIMENTAL
Intervention: HP±10% sodium ascorbate for 10min
Number of subjects: 60
Study 36106470 — intervention group
Group type: EXPERIMENTAL
Intervention: HP±10% alpha‐tocopherol for 10min
Number of subjects: 60
Study 36106470 — intervention group
Group type: COMPARATOR
Intervention: Bleaching with 40% hydrogen peroxide (HP)
Number of subjects: 60
Study 36106470 — intervention group
Group type: COMPARATOR
Intervention: No bleaching (negative control)
Number of subjects: 60
Study 33626480 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate therapy (statin + ezetimibe)
Number of subjects: 80
Study 33626480 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 80
Study 33028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) for 6 min
Number of subjects: 0
Study 33028207 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP + 35 W exercise for 6 min
Number of subjects: 0
Study 33028207 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP + 45 W exercise for 6 min
Number of subjects: 0
Study 33028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of rate pressure product (RPP) after stress
Number of subjects: 0
Study 33028207 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic volume (LVEDV) after stress
Number of subjects: 0
Study 35603451 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 35603451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35258371 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y transarterial radioembolization (TARE)
Number of subjects: 72
Study 35258371 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin drug-eluting bead (DEB) TACE
Number of subjects: 72
Study 33198710 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed monovision (dominant eye -2.00D, non-dominant eye -0.50D)
Number of subjects: 46
Study 33198710 — intervention group
Group type: COMPARATOR
Intervention: Conventional monovision (dominant eye -0.50D, non-dominant eye -2.00D)
Number of subjects: 46
Study 33198710 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossed monovision
Number of subjects: 46
Study 33198710 — intervention group
Group type: COMPARATOR
Intervention: Conventional monovision
Number of subjects: 46
Study 36058514 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention with 10 home visits over 1 year
Number of subjects: 223
Study 36058514 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 223
Study 36058514 — intervention group
Group type: COMPARATOR
Intervention: Certified Asthma Educator (AE‐C) intervention with 2 sessions in a clinic over 1 year
Number of subjects: 223
Study 33545542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cacao polyphenol-rich chocolate plus water (C)
Number of subjects: 48
Study 33545542 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 48
Study 36280924 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-gauge epidural needle
Number of subjects: 126
Study 36280924 — intervention group
Group type: COMPARATOR
Intervention: 18-gauge epidural needle
Number of subjects: 126
Study 33726802 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOM powered prosthesis
Number of subjects: 12
Study 33726802 — intervention group
Group type: COMPARATOR
Intervention: Unpowered prosthesis
Number of subjects: 12
Study 35120579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) oil supplementation (two soft gels)
Number of subjects: 46
Study 35120579 — intervention group
Group type: COMPARATOR
Intervention: Paraffin oil (control)
Number of subjects: 46
Study 32225045 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP) for improving the uptake of HIVST among men in Rwanda
Number of subjects: 0
Study 35850136 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (50 minutes along with conventional medical treatment)
Number of subjects: 62
Study 35850136 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (control group)
Number of subjects: 62
Study 35850136 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 62
Study 32200610 — intervention group
Group type: EXPERIMENTAL
Intervention: CFNB with basal infusion of ropivacaine plus boluses (Group III)
Number of subjects: 90